At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PRCT PROCEPT BioRobotics
Closed 08-04 16:00:00 EDT
18.28
-0.10
-0.54%
盘后17.15
-1.13-6.16%
19:57 EDT
High18.49Low17.55Vol3.73M
Open17.57D1 Closing18.38Amplitude5.10%
Mkt Cap1.04BTradable Cap986.23MTotal Shares56.91M
T/O67.76MT/O Rate6.92%Tradable Shares53.95M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

PROCEPT BioRobotics Q2 EPS $(0.47) Misses $(0.46) Estimate, Sales $94.498M Beat $92.893M Estimate
Benzinga Earnings  ·  04:06
PROCEPT BioRobotics Q2 EPS $(0.47) Misses $(0.46) Estimate, Sales $94.498M Beat $92.893M Estimate
William Blair downgrades PROCEPT BioRobotics (PRCT) to a Hold
TIPRANKS  ·  07:35
William Blair downgrades PROCEPT BioRobotics (PRCT) to a Hold
Procept Biorobotics Corp Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  05:41
Procept Biorobotics Corp Reports Results for the Quarter Ended June 30 - Earnings Summary
Procept BioRobotics Q2 Net Loss Widens to $26.86 Million; Revenue Rises 19% to $94.5 Million
Reuters  ·  04:40
Procept BioRobotics Q2 Net Loss Widens to $26.86 Million; Revenue Rises 19% to $94.5 Million
Procept BioRobotics Q2 Revenue Beats Estimates on Hydros Demand
Reuters  ·  04:31
Procept BioRobotics Q2 Revenue Beats Estimates on Hydros Demand
Procept Biorobotics Q2 Revenue USD 94.498 Million Vs. IBES Estimate USD 92.9 Million
Reuters  ·  04:06
Procept Biorobotics Q2 Revenue USD 94.498 Million Vs. IBES Estimate USD 92.9 Million
Procept Biorobotics Outlook FY Gross Margin 65%
THOMSON REUTERS  ·  04:05
Procept Biorobotics Outlook FY Gross Margin 65%
Procept Biorobotics Outlook FY Revenue USD 390-410 Million
THOMSON REUTERS  ·  04:05
Procept Biorobotics Outlook FY Revenue USD 390-410 Million
Procept Biorobotics Corp - Expects Fy2026 U.S. Procedure Volume of 54,000-56,000, up 25%-29%
THOMSON REUTERS  ·  04:05
Procept Biorobotics Corp - Expects Fy2026 U.S. Procedure Volume of 54,000-56,000, up 25%-29%
PROCEPT BioRobotics Reports Second Quarter 2026 Financial Results
GlobeNewswire  ·  04:05
PROCEPT BioRobotics Reports Second Quarter 2026 Financial Results
PROCEPT BioRobotics Lawsuit Puts PRCT Investor Losses in Focus After Alleged Handpiece Demand Disclosures
TIPRANKS  ·  07-31
PROCEPT BioRobotics Lawsuit Puts PRCT Investor Losses in Focus After Alleged Handpiece Demand Disclosures
Earning Preview: PROCEPT BioRobotics Q2 revenue is expected to increase by 21.59%, and institutional views are bullish
Earnings Agent  ·  07-29
Earning Preview: PROCEPT BioRobotics Q2 revenue is expected to increase by 21.59%, and institutional views are bullish
Medical Robotics Firm PROCEPT BioRobotics Faces Class Action Over Hidden Discount Scheme
Deep News  ·  07-29
Medical Robotics Firm PROCEPT BioRobotics Faces Class Action Over Hidden Discount Scheme
Medical Robotics Company PROCEPT BioRobotics Confronts Securities Fraud Lawsuit Over Discount Disclosure Issues
Deep News  ·  07-29
Medical Robotics Company PROCEPT BioRobotics Confronts Securities Fraud Lawsuit Over Discount Disclosure Issues
Procept BioRobotics Coverage Assumed by UBS at Neutral vs Previous Rating of Buy
Dow Jones  ·  07-29
Procept BioRobotics Coverage Assumed by UBS at Neutral vs Previous Rating of Buy
UBS Downgrades PROCEPT BioRobotics to Neutral From Buy, Cuts Price Target to $20 From $30
MT Newswires Live  ·  07-28
UBS Downgrades PROCEPT BioRobotics to Neutral From Buy, Cuts Price Target to $20 From $30
Shareholder Action Against Surgical Robotics Firm Over Alleged Deceptive Sales Practices
Deep News  ·  07-27
Shareholder Action Against Surgical Robotics Firm Over Alleged Deceptive Sales Practices
Analysts’ Opinions Are Mixed on These Healthcare Stocks: TG Therapeutics (TGTX), Protagonist Therapeutics (PTGX) and PROCEPT BioRobotics (PRCT)
TIPRANKS  ·  07-16
Analysts’ Opinions Are Mixed on These Healthcare Stocks: TG Therapeutics (TGTX), Protagonist Therapeutics (PTGX) and PROCEPT BioRobotics (PRCT)
Mobia Medical Names Reza Zadno to Board as Independent Director
Reuters  ·  07-16
Mobia Medical Names Reza Zadno to Board as Independent Director
Mobia Medical Appoints Reza Zadno, Ph.d., to Its Board of Directors
THOMSON REUTERS  ·  07-16
Mobia Medical Appoints Reza Zadno, Ph.d., to Its Board of Directors

Introduction

Company Name.
PROCEPT BioRobotics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Issue price:
--